Business UpdateJul 7, 2026, 07:01 AM
Avalo Therapeutics to Host Investor Meetings
AI Summary
Avalo Therapeutics, Inc. announced that its management will host one-on-one investor meetings during the Leerink Partners Therapeutics Forum on July 15, 2026, in Boston. The company is a clinical-stage biotechnology firm dedicated to developing therapeutics targeting the IL-1β pathway for immune-mediated inflammatory diseases, with its lead asset abdakibart recently showing positive Phase 2 data.
Key Highlights
- Avalo Therapeutics management will host one-on-one investor meetings.
- Meetings are scheduled for July 15, 2026.
- The event is the Leerink Partners Therapeutics Forum in Boston.
- Avalo is a clinical-stage biotech focused on IL-1β pathway therapeutics.
- Lead asset abdakibart recently reported positive Phase 2 data in hidradenitis suppurativa.
- The company is also advancing AVTX-010, a next-generation anti-IL-1β mAb.
Price Impact
More from AVTX